Hussman Strategic Advisors Inc. Has $1.36 Million Stock Position in GeneDx Holdings Corp. $WGS

Hussman Strategic Advisors Inc. lessened its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 40.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,600 shares of the company’s stock after selling 8,400 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in GeneDx were worth $1,358,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. AlphaQuest LLC raised its position in shares of GeneDx by 351.5% in the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after buying an additional 594 shares in the last quarter. Tower Research Capital LLC TRC raised its position in GeneDx by 479.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,818 shares of the company’s stock valued at $168,000 after purchasing an additional 1,504 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in GeneDx by 61.0% during the second quarter. Ameritas Investment Partners Inc. now owns 1,917 shares of the company’s stock valued at $177,000 after purchasing an additional 726 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in GeneDx during the third quarter worth $187,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of GeneDx in the 2nd quarter valued at $204,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Stock Performance

NASDAQ:WGS opened at $95.29 on Thursday. The stock’s 50-day moving average is $135.44 and its 200-day moving average is $124.36. GeneDx Holdings Corp. has a 1-year low of $55.17 and a 1-year high of $170.87. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. The stock has a market cap of $2.75 billion, a P/E ratio of 1,058.78 and a beta of 2.01.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.28 by $0.21. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. The business had revenue of $116.74 million for the quarter, compared to the consensus estimate of $104.33 million. Equities research analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

WGS has been the subject of several recent analyst reports. Canaccord Genuity Group upped their price objective on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. BTIG Research increased their target price on shares of GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Guggenheim restated a “buy” rating and issued a $170.00 price target (up from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Finally, Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 2nd. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus target price of $138.13.

Insider Transactions at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 10,857 shares of GeneDx stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $143.89, for a total transaction of $1,562,213.73. Following the transaction, the chief executive officer directly owned 14,237 shares of the company’s stock, valued at approximately $2,048,561.93. The trade was a 43.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kevin Feeley sold 3,855 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $143.87, for a total value of $554,618.85. Following the completion of the sale, the chief financial officer owned 8,731 shares in the company, valued at $1,256,128.97. This trade represents a 30.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 57,617 shares of company stock worth $8,992,161. Company insiders own 29.60% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.